NEW YORK, April 7, 2021 /PRNewswire/ -- AIkido Pharma
Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today announced
that it has been granted an exclusive sublicense to technology
related to the use of novel and proprietary central nervous system
(CNS) homing peptides for the therapeutic treatment of
neuroinflammatory disease in cancer patients.
The homing peptides covered by the sublicense can be used to
facilitate the delivery of therapeutic agents to inflamed CNS
tissue. Psychedelics such as psilocybin have been shown to
have anti-inflammatory activity in addition to their potential
efficacy for treatment of neurological disorders such as anxiety,
depression and post-traumatic stress disorder (PTSD). Studies
indicate that neuroinflammation of the brain and other CNS tissues
in cancer patients contributes to, among other symptoms, the onset
of cancer cachexia, which is characterized by loss of appetite,
extreme weight loss and muscle wasting.
Anthony Hayes, CEO of AIkido
Pharma, stated, "The novel homing peptides covered under this
sublicense have the potential to allow the direct delivery of
psilocybin to inflamed CNS tissue in cancer patients. This
sublicense culminates our Letter of Intent previously announced on
February 16, 2021. It
complements our recently announced support of the psilocybin
research for PTSD treatment at Mount Sinai Center for Psychedelic
Psychotherapy and Trauma Research."
About AIkido Pharma Inc.
AIkido Pharma Inc. was
initially formed in 1967 and is a biotechnology Company with a
diverse portfolio of small-molecule anti-cancer therapeutics.
The Company's platform consists of patented technology from leading
universities and researchers, and we are currently in the process
of developing an innovative therapeutic drug platform through
strong partnerships with world renowned educational institutions,
including The University of Texas at
Austin and University
of Maryland at Baltimore. Our diverse pipeline of
therapeutics includes therapies for pancreatic cancer and prostate
cancer. We are constantly seeking to grow our pipeline to treat
unmet medical needs in oncology. The Company is also
developing a broad-spectrum antiviral platform that may potentially
inhibit replication of multiple viruses including Influenza virus,
SARS-CoV (coronavirus), MERS-CoV, Ebolavirus and Marburg virus.
Certain statements in this press release constitute
"forward-looking statements" within the meaning of the federal
securities laws. Words such as "may," "might," "will," "should,"
"believe," "expect," "anticipate," "estimate," "continue,"
"predict," "forecast," "project," "plan," "intend" or similar
expressions, or statements regarding intent, belief, or current
expectations, are forward-looking statements. While the Company
believes these forward-looking statements are reasonable, undue
reliance should not be placed on any such forward-looking
statements, which are based on information available to us on the
date of this release. These forward-looking statements are based
upon current estimates and assumptions and are subject to various
risks and uncertainties, including without limitation those set
forth in the Company's filings with the SEC, not limited to Risk
Factors relating to its business contained therein. Thus, actual
results could be materially different. The Company expressly
disclaims any obligation to update or alter statements whether as a
result of new information, future events or otherwise, except as
required by law.
Brett Maas, Managing Partner
Phone: (646) 536-7331
AIkido Pharma Inc.:
View original content to download
SOURCE AIkido Pharma Inc.